The Centers for Medicare and Medicaid Services (CMS) issued a new shared HCPCS billing code for Synvisc-One^® and SYNVISC^® (hylan G-F 20) effective for dates of service on or after January 1^st 2010.

J7325, HYALURONAN OR DERIVATIVE, SYNVISC OR SYNVISC-ONE, FOR INTRA-ARTICULAR INJECTION, 1 MG

2010 billing instructions for Synvisc-One and SYNVISC:

The unique J-code assigned to Synvisc-One and SYNVISC, J7325, significantly streamlines the reimbursement process. Synvisc-One and SYNVISC are eligible for reimbursement by commercial payers and Medicare. However, specific policies vary across insurers and from plan to plan. Use the links tbelow to find reimbursement information for the following payer types:

• Commercial Payers – Understand the reimbursement guidelines for commercial payers, including specialty pharmacy.
• Medicare – Find out about Medicare reimbursement across different settings of care
• Medicaid – Understand general reimbursement requirements across state Medicaid agencies

Providers retain responsibility for determining reimbursement and insurance issues related to their patients. Genzyme cannot be responsible for failure of a provider to obtain reimbursement.